Kangenbei: Kangenbei Group intends to transfer 2% of the company's shares to the controlling shareholder.

On December 22, Conba announced that its second largest shareholder, Conba Group, plans to reduce its stake in the company by no more than 50.659 million shares through a block trade, with the reduction not exceeding 2% of the company's total share capital. Zhejiang Pharmaceutical Group, the controlling shareholder of the company, is the acquirer of the block trade for this Conba Group share reduction.